bovnews15h
Why Did Biomarin Pharmaceutical Inc (BMRN) Stock Plunge -5.87% Last Week?
On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...
Zacks.com on MSN21h
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...
Zacks.com on MSN1d
BMRN vs. INCY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...
bovnews7d
Biomarin Pharmaceutical Inc (BMRN) Stock Settles at $69.91: What’s Contributing to This Price Point?
On Tuesday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $69.91 which represents a decrease of $-0.22 or -0.31% from the prior close of $70.13. The stock opened at $69.78 ...
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...
BioMarin price target raised to $106 from $104 at UBS
UBS raised the firm’s price target on BioMarin (BMRN) to $106 from $104 and keeps a Buy rating on the shares. BioMarin ...
BioMarin Pharmaceutical: Strategic Growth and Shareholder Value Enhancement Drive Buy Rating
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Joseph Schwartz has ...
Balanced Hold Rating on BioMarin Amid Strong Q3 Performance But Modest Long-Term Growth Prospects
BioMarin Pharmaceutical (BMRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 52-Week Low on Disappointing Earnings
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
On October 31, 2024, Biomarin Pharmaceutical Inc (NASDAQ:BMRN) filed its 10-Q report, providing a snapshot of the company's financial health and operational performance. As a biotechnology firm ...